Companies: 10,795·Total market cap: $144.5T
Pardes Biosciences, Inc.

Pardes Biosciences, Inc.

PRDSNASDAQHealthcare
$2.18
+$0.02(+0.93%)
Market Cap$135185724
P/E Ratio
52W High$3.67
52W Low$0.75

Pardes Biosciences, Inc. (PRDS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

prds · pe ratio · data through Dec 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Pardes Biosciences, Inc. (PRDS) measures how much investors pay for each dollar of the company's trailing earnings. PRDS's current PE ratio of N/A is calculated by dividing its stock price of $2.18 by its TTM earnings per share of -$1.61.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31

Forward P/E
N/A
EPS (TTM)
-$1.61
TTM · diluted EPS
PEG Ratio
-2.79
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Pardes Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2020 – 2022 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Pardes Biosciences, Inc.
Pardes Biosciences, Inc.You
PRDS
$135MN/A-$1.61
aTyr Pharma, Inc.
aTyr Pharma, Inc.
ATYR
$43MN/A-$0.80
Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc.
DBTX
$123MN/A-$2.52
Graybug Vision, Inc.
Graybug Vision, Inc.
GRAY
$121MN/A-$0.00
HilleVax, Inc.
HilleVax, Inc.
HLVX
$105MN/A-$3.00
Kinnate Biopharma Inc.
Kinnate Biopharma Inc.
KNTE
$125MN/A-$2.42
NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.
NGM
$129MN/A-$1.73

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 3 of 3 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-12-31Latest
FY2022
$-1.61
2021-12-31
FY2021
$-0.68
2020-12-31
FY2020
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Pardes Biosciences, Inc. (PRDS) measures how much investors pay for each dollar of the company's trailing earnings. PRDS's current PE ratio of N/A is calculated by dividing its stock price of $2.18 by its TTM earnings per share of -$1.61.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.18 ÷ -$1.61 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

PRDS pe ratio · 6 questions

PRDS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.18 and TTM EPS of -$1.61. Data sourced from Financial Modeling Prep via PRDS's SEC 10-K and 10-Q filings.

PRDS PE ratioWhat is PRDS PE ratioCurrent PE ratio of PRDSPRDS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Pardes Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09